Droplet Microfluidic Innovations for Single-Cell Applications
Samplix ApS develops microfluidics technologies for high-throughput, function-first single-cell analysis. Our solutions help researchers study what individual cells actually do — not just which markers they express.
At the core of our technology is the generation of highly uniform microfluidic double-emulsion droplets. These droplets act as isolated microreactors fully compatible with standard flow cytometers and cell sorters, allowing scientists to integrate droplet-based workflows directly into existing laboratory infrastructure without specialized detection systems.
Samplix technologies support a wide range of applications, including single-cell secretion assays, cell–cell interaction studies, functional screening, and analysis of cellular heterogeneity. By combining microfluidics with widely adopted analytical instruments, we enable scalable, accessible, and reproducible single-cell experimentation.
Samplix was founded on the vision that high-throughput cellular screening should be accessible without specialized instrumentation. From the beginning, our goal was to democratize screening throughput by enabling researchers to leverage widely available, state-of-the-art laboratory technologies.
To realize this vision, Samplix focused on microfluidic double-emulsion droplets — a format uniquely compatible with standard flow cytometers and cell sorters. By engineering highly stable and uniform droplets, we enabled researchers to analyse and sort droplet-encapsulated live cells using instruments already established as gold standards in research and clinical laboratories.
This approach allowed scientists to move beyond traditional bulk measurements and perform functional single-cell assays at exceptional throughput, while preserving cell viability for downstream applications.
With the introduction of the Xdrop microfluidic platform, Samplix provided a practical and scalable way to integrate droplet-based workflows into existing experimental pipelines. Today, Samplix technologies support applications in single-cell analysis, functional screening, and cellular heterogeneity research across disciplines worldwide.
CEO
Henrik Pfundheller provides expertise in business strategy, building global commercial teams, and establish competent commercial leadership within the areas of genomics and immunology. He has listed one life science company and has been engaged with Immudex, QIAGEN, Exiqon, RiboTask and Denator.
LI Logo svg original
CCO
Trine Overgaard Østerbye provides expertise in leading commercial operations in life sciences startup companies, including companies working within the areas of immunology other cell functionality space. She has been engaged with BioPorto Diagnostics, Svar Life Sciences, and Kementec Solutions.
Chief Development Officer, Product and Application Development
Peter Mouritzen provides expertise in documenting the many applications of the Xdrop technology and builds relationships with key opinion leaders across the globe. He has listed one life science company and has been engaged with QIAGEN and Exiqon.
VP Intellectual Property Rights
Søren Echwald Morgenthaler provides expertise in patent strategy, freedom to operate analysis and business strategy. He has listed one life sciences company and is or has been engaged with Anapa Biotech, Exiqon and Novo Nordisk.
Chairman & Co-Founder
Michael Obermayer is an experienced board member with extensive knowledge in Business Strategy, and Corporate Development. With previous roles at McKinsey & Co., and Fjord Capital Partners, Michael brings a wealth of global experience and strategic acumen to Samplix ApS.
Board member
Lars Krogsgaard is a professional board member with extensive experience in strategic development, business development, risk management, and financing. With a proven track record as an active investor and board member in over 25 Nordic companies, Lars brings valuable insights to Samplix ApS.
Henrik Christensen, Founder and CEO of Kementec Solutions, and serial entrepreneur, brings extensive expertise in biomedical and life sciences. He also holds key board positions, including Chairman of DiaLab and HC Handel & Invest. Henrik’s leadership is strengthened by his participation in INSEAD’s Advanced Board Program, fostering strategic business growth.
Upcoming meetings, webinars, and industry events
Meet us at these events in the first half of 2026:
Product releases, partnerships, and company news
Samplix builds on initial successes in EIC Accelerator co-funded project
January 5, 2024
In 2023, the EIC (European Innovation Council) committed to aiding Samplix in the development of our microfluidics technology for functional characterization of single cells. This technology is crucial for revealing the heterogeneity of immune cells fighting cancer, among other key applications. The incredible potential of cell and immune therapy is currently limited by technical challenges related to the standard analysis of immune cells in bulk, which neglects their heterogeneity.
Having made good progress in the EIC Accelerator-funded project in 2023, Samplix is opening 2024 with a tight focus on the ways our Xdrop instruments can best serve the cell therapy research community. We’re proud to have been chosen by the EIC and committed to ensuring vastly improved workflows for cell therapy research, including cytokine, granzyme, antibody, and cell killing applications.
Learn more
See the latest news about product releases, webinars and events, partnerships and more.
